Extended-release physostigmine in Alzheimer disease: a multicenter, double-blind, 12-week study with dose enrichment. Physostigmine Study Group.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Archives of General Psychiatry

• Publication date

  2000-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1001/ARCHPSYC.57.2.157PMID 10665618
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A 24-week randomized trial of controlled-release physostigmine in patients with Alzheimer’s disease

  1999cited by this paper
• DONEPEZIL STUDY GROUP. A 24-WEEK, DOUBLE BLIND, PLACEBO-CONTROLLED TRIAL OF DONEPEZIL IN PATIENTS WITH ALZHEIMER'S DIS-EASE

  1998cited by this paper
• A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease

  1998cited by this paper
• Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease

  1998cited by this paper
• Metrifonate treatment of the cognitive deficits of Alzheimer's disease

  1998cited by this paper
• The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. The Donepezil Study Group.

  1996cited by this paper
• A multicenter double-blind study of controlled-release physostigmine for the treatment of symptoms secondary to Alzheimer's disease. Physostigmine Study Group.

  1996cited by this paper
• A multicenter double-blind study of controlled-release physostigmine for the treatment of symptoms secondary to Alzheimer's disease

  1996cited by this paper
• The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicentre, randomized, double-blind, placebo-controlled trial

  1996cited by this paper
• Clinical Global Impressions 1976

  1995cited by this paper
• Effectiveness and safety of velnacrine for the treatment of Alzheimer's disease. A double-blind, placebo-controlled study. Mentane Study Group.

  1995cited by this paper
• Effectiveness and Safety of Velnacrine for the Treatment of Alzheimer's Disease: A Double-blind, Placebo-Controlled Study

  1995cited by this paper
• A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group.

  1994cited by this paper
• Alzheimer's disease: pathophysiology and the hope for therapy.

  1994cited by this paper
• The Clinician Interview‐ Based Impression (CIBI)

  1994cited by this paper
• A 30-Week Randomized Controlled Trial of High-Dose Tacrine in Patients With Alzheimer's Disease

  1994cited by this paper
• The US economic and social costs of Alzheimer's disease revisited.

  1994cited by this paper
• A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group.

  1992cited by this paper
• A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group.

  1992cited by this paper
• Chronic Oral Physostigmine Without Lecithin Improves Memory in Alzheimer's Disease

  1989cited by this paper
• Plasma physostigmine concentrations after controlled-release oral administration.

  1989cited by this paper
• Measurement of quality-of-life changes in patients with Alzheimer's disease.

  1989cited by this paper
• Clinical predictors of course for Alzheimer patients in a longitudinal study: a preliminary report.

  1988cited by this paper
• Tetrahydroaminoacridine, 3,4 diaminopyridine and physostigmine: direct comparison of effects on memory in aged primates.

  1988cited by this paper
• Effects of oral physostigmine in Alzheimer's disease

  1987cited by this paper
• Oral physostigmine treatment of patients with Alzheimer's disease.

  1985cited by this paper
• A new rating scale for Alzheimer's disease.

  1984cited by this paper
• Clinical diagnosis of Alzheimer's disease

  1984cited by this paper
• Discrete sequential boundaries for clinical trials

  1983cited by this paper
• Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain.

  1982cited by this paper
• Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis

  1981cited by this paper
• Pathological verification of ischemic score in differentiation of dementias

  1980cited by this paper
• A multiple testing procedure for clinical trials.

  1979cited by this paper
• Evidence for a direct cholinergic involvement in the scopolamine-induced amnesia in monkeys: effects of concurrent administration of physostigmine and methylphenidate with scopolamine.

  1978cited by this paper
• Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia.

  1978cited by this paper
• “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician

  1975cited by this paper
• Assessment of older people: self-maintaining and instrumental activities of daily living.

  1969cited by this paper

• Physostigmine modulates hippocampal GABAergic neurotransmission via α7 nicotinic acetylcholine receptors.

  2026cites this paper
• Improving cognitive impairment through chronic consumption of natural compounds/extracts: a systematic review and meta-analysis of randomized controlled trials

  2025cites this paper
• Natural Products from Plants and Algae for Treatment of Alzheimer’s Disease: A Review

  2022cites this paper
• Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease.

  2020cites this paper
• Features and outcomes of drugs for combination therapy as multi-targets strategy to combat Alzheimer's disease.

  2018cites this paper
• List of excluded studies and reasons for exclusion

  2017cites this paper
• Alzheimer’s Disease and Animal Models in Retrospect

  2014cites this paper
• Integrating theories and concepts: formulation driven CBT for a client with a diagnosis of schizo-affective disorder.

  2013cites this paper
• Alkaloids and Inhibitory Effects Against Enzymes Linked to Neurodegenerative Diseases (Physostigmine, Galanthamine, Huperzine, etc.)

  2013cites this paper
• Physostigmine and Galanthamine Bind in the Presence of Agonist at the Canonical and Noncanonical Subunit Interfaces of a Nicotinic Acetylcholine Receptor

  2013cites this paper
• Cognitive impairment : quantification and possibilities for pharmacological treatment

  2013cites this paper
• A subchronic application period of glucocorticoids leads to rat cognitive dysfunction whereas physostigmine induces a mild neuroprotection

  2010cites this paper
• The cholinesterase inhibitor physostigmine for the local treatment of dry mouth: a randomized study.

  2009cites this paper
• Activation and Block of the Adult Muscle-Type Nicotinic Receptor by Physostigmine: Single-Channel Studies

  2008cites this paper
• Study design factors and patient demographics and their effect on the decline of placebo-treated subjects in randomized clinical trials in Alzheimer's disease.

  2007cites this paper
• A novel oxidative degradation pathway of indomethacin under the stressing by hydrogen peroxide

  2005cites this paper
• Pharmacological Treatment of Dementia: Summary

  2004cites this paper
• Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer’s disease

  2004cites this paper
• Pharmacotherapy in the treatment of Alzheimer's disease: an update.

  2004cites this paper
• The age gap between patients in clinical studies and in the general population: a pitfall for dementia research.

  2004cites this paper
• Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis.

  2003cites this paper
• Influence of acetylcholine levels on the binding of a SPECT nicotinic acetylcholine receptor ligand [123I]5‐I‐A‐85380

  2003cites this paper
• Clinically tested drugs for Alzheimer’s disease

  2003cites this paper
• Alzheimer's disease: a review for the ophthalmologist.

  2001cites this paper
• Cholinesterase inhibitors for behavioral disturbance in dementia

  2001cites this paper
• Physostigmine for dementia due to Alzheimer's disease

  2001cites this paper
• Physostigmine for Alzheimer's disease.

  2001cites this paper
• Drug treatment in dementia

  2001cites this paper
• Donepezil and related cholinesterase inhibitors as mood and behavioral controlling agents

  2000cites this paper
• Drug treatment in dementia

  2000cites this paper